Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2024
Business Overview: Propanc is a pre-revenue biopharmaceutical company developing PRP, a novel pancreatic proenzyme therapy designed to prevent cancer recurrence and metastasis in solid tumors (pancreatic, ovarian, colorectal). The company is currently in the preclinical phase, with plans to submit a Clinical Trial Application (CTA) in mid-2025 and commence a Phase Ib study in late 2025, subject to financing.
Key Financial Metrics
| Metric | Fiscal Year 2024 | Fiscal Year 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,820,528) | $(2,660,566) |
| Net Loss Available to Common Stockholders | $(2,013,488) | $(3,126,839) |
| Cash and Cash Equivalents (End of Period) | $21,085 | $10,047 |
| Net Cash Used in Operating Activities | $(935,118) | $(1,105,251) |
| Net Cash Provided by Financing Activities | $941,894 | $1,113,719 |
| Total Assets | $72,365 | $60,328 |
| Total Liabilities | $3,851,424 | $3,177,507 |
| Working Capital Deficit | $(3,767,341) | $(3,139,190) |
| Accumulated Deficit | $(66,698,220) | $(64,684,732) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $840,000 (31.6%) compared to the prior year, primarily driven by a $847,000 swing in the change in fair value of derivative liabilities (from a loss of $530,330 in 2023 to a gain of $316,537 in 2024) due to declining stock prices.
- Operating Expenses: Total operating expenses decreased by approximately $240,000. Administration expenses dropped by $246,000 due to reduced consulting, legal, and stock-based compensation costs, partially offset by a $91,000 increase in marketing expenses.
- Debt and Derivatives: Interest expense increased by $133,000 due to higher amortization of debt discounts and accretion of put premiums. The company recognized a derivative expense of $141,012 in 2024, compared to $0 in 2023, related to new convertible notes.
- Stock Issuance: The company issued approximately 446 million shares of common stock in 2024 (compared to ~5.8 million in 2023) primarily through the conversion of convertible notes, significantly increasing the share count to 478.8 million outstanding.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The company has a "Going Concern Qualification" from its auditors. With only $21,085 in cash and a working capital deficit of $3.77 million, management states it does not have sufficient cash to meet obligations for the next 12 months without additional financing.
- Financing Needs: The company anticipates needing approximately $6.5 million to fund the planned Phase Ib clinical trial. It is actively seeking debt and equity financing, which may result in significant dilution to existing shareholders.
- Development Timeline: Management plans to submit the CTA in the second half of 2025 and commence the Phase Ib study in the second half of 2025. A Phase IIa proof of concept is targeted for completion in 3-4 years.
- Material Weaknesses: The company identified material weaknesses in internal controls, including lack of written documentation, insufficient segregation of duties, lack of an audit committee, and insufficient monitoring of financial reporting.
- Reverse Stock Split: On August 7, 2024, shareholders approved a reverse stock split (ratio between 1:10,000 and 1:100,000) pending FINRA approval to maintain OTC listing standards.
- Debt Defaults: Several convertible notes (totaling $83,000 principal) are currently in default, accruing default interest rates up to 24% per annum.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise the required $6.5 million for clinical trials given the current cash balance of ~$21k and significant debt obligations.
- Debt Structure: Review the terms of the convertible notes in default and the potential for forced conversion or acceleration of debt payments.
- Dilution Risk: Assess the impact of the proposed reverse stock split and the massive issuance of shares via debt conversion on existing shareholder value.
- Internal Controls: Confirm the timeline and funding for remediation of material weaknesses in financial reporting and the establishment of an audit committee.
- Regulatory Milestones: Monitor the submission and approval of the Clinical Trial Application (CTA) in Australia, as this is the critical path to value inflection.